메뉴 건너뛰기




Volumn 9, Issue 6, 2011, Pages 423-433

Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: A pooled analysis from phase III studies

Author keywords

efficacy; elderly; liraglutide; tolerability; type 2 diabetes

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

EID: 83455251226     PISSN: 15435946     EISSN: 18767761     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2011.09.007     Document Type: Article
Times cited : (55)

References (39)
  • 1
    • 79957651158 scopus 로고    scopus 로고
    • National Diabetes Information Clearinghouse Accessed October 3, 2011
    • National Diabetes Information Clearinghouse National diabetes statistics, 2011 http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#y-people Accessed October 3, 2011
    • National Diabetes Statistics, 2011
  • 2
    • 2342466734 scopus 로고    scopus 로고
    • Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030
    • DOI 10.2337/diacare.27.5.1047
    • S. Wild, G. Roglic, A. Green Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053 (Pubitemid 38579764)
    • (2004) Diabetes Care , vol.27 , Issue.5 , pp. 1047-1053
    • Wild, S.1    Roglic, G.2    Green, A.3    Sicree, R.4    King, H.5
  • 3
    • 33749916374 scopus 로고
    • Food and Drug Administration Accessed October 3, 2011
    • Food and Drug Administration Guideline for Industry Studies in support of special populations: geriatrics http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm073131.pdf August 1994 Accessed October 3, 2011
    • (1994) Guideline for Industry Studies in Support of Special Populations: Geriatrics
  • 4
    • 59049091826 scopus 로고    scopus 로고
    • Pharmacological management of glycemic control in the geriatric patient with type 2 diabetes mellitus
    • J.J. Neumiller, S.M. Setter, B.J. Gates Pharmacological management of glycemic control in the geriatric patient with type 2 diabetes mellitus Consult Pharm 24 2009 45 63
    • (2009) Consult Pharm , vol.24 , pp. 45-63
    • Neumiller, J.J.1    Setter, S.M.2    Gates, B.J.3
  • 5
    • 0035114670 scopus 로고    scopus 로고
    • Management of type 2 diabetes mellitus in the elderly: Special considerations
    • J. Rosenstock Management of type 2 diabetes mellitus in the elderly: special considerations Drugs Aging 18 2001 31 44 (Pubitemid 32182131)
    • (2001) Drugs and Aging , vol.18 , Issue.1 , pp. 31-44
    • Rosenstock, J.1
  • 6
    • 2142769878 scopus 로고    scopus 로고
    • Treatment of patients over 64 years of age with type 2 diabetes: Experience from nateglinide pooled database retrospective analysis
    • DOI 10.2337/diacare.26.7.2075
    • S. Del Prato, R.J. Heine, L. Keilson Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis Diabetes Care 26 2003 2075 2080 (Pubitemid 41184255)
    • (2003) Diabetes Care , vol.26 , Issue.7 , pp. 2075-2080
    • Del Prato, S.1    Heine, R.J.2    Keilson, L.3    Guitard, C.4    Shen, S.G.5    Emmons, R.P.6
  • 7
    • 67651245065 scopus 로고    scopus 로고
    • Potentially severe drug interactions in elderly outpatients: Results of an observational study of an administrative prescription database
    • A. Nobili, L. Pasina, M. Tettamanti Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database J Clin Pharm Ther 34 2009 377 386
    • (2009) J Clin Pharm Ther , vol.34 , pp. 377-386
    • Nobili, A.1    Pasina, L.2    Tettamanti, M.3
  • 8
    • 67649510151 scopus 로고    scopus 로고
    • Medication errors in elderly people: Contributing factors and future perspectives
    • D. Fialová, G. Onder Medication errors in elderly people: contributing factors and future perspectives Br J Clin Pharmacol 67 2009 641 645
    • (2009) Br J Clin Pharmacol , vol.67 , pp. 641-645
    • Fialová, D.1    Onder, G.2
  • 9
    • 0032434422 scopus 로고    scopus 로고
    • Estimates on the incidence of antidiabetic drug-induced severe hypoglycaemia in Hong Kong
    • DOI 10.1002/(SICI)1099-1557(199811/12)7:6<411::AID-PDS379>3.0.CO;2- U
    • T.Y. Chan Estimates on the incidence of antidiabetic drug-induced severe hypoglycaemia in Hong Kong Pharmacoepidemiol Drug Saf 7 1998 411 414 (Pubitemid 29047898)
    • (1998) Pharmacoepidemiology and Drug Safety , vol.7 , Issue.6 , pp. 411-414
    • Chan, T.Y.K.1
  • 10
  • 11
    • 68149117576 scopus 로고    scopus 로고
    • Hypoglycemia unawareness in older compared to middle-aged patients with type 2 diabetes
    • J.P. Bremer, K. Jauch-Chara, M. Hallschmid Hypoglycemia unawareness in older compared to middle-aged patients with type 2 diabetes Diabetes Care 32 2009 1513 1517
    • (2009) Diabetes Care , vol.32 , pp. 1513-1517
    • Bremer, J.P.1    Jauch-Chara, K.2    Hallschmid, M.3
  • 13
    • 0022461548 scopus 로고
    • Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
    • M.A. Nauck, E. Homberger, E.G. Siegel Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 63 1986 492 498 (Pubitemid 16035703)
    • (1986) Journal of Clinical Endocrinology and Metabolism , vol.63 , Issue.2 , pp. 492-498
    • Nauck, M.A.1    Homberger, E.2    Siegel, E.G.3
  • 14
    • 0031033531 scopus 로고    scopus 로고
    • Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
    • DOI 10.1007/s001250050664
    • J. Rachman, B.A. Barrow, J.C. Levy Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 40 1997 205 211 (Pubitemid 27060294)
    • (1997) Diabetologia , vol.40 , Issue.2 , pp. 205-211
    • Rachman, J.1    Barrow, B.A.2    Levy, J.C.3    Turner, R.C.4
  • 15
    • 0024338802 scopus 로고
    • GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans
    • DOI 10.1007/BF01540341
    • B.T. Schjoldager, P.E. Mortensen, J. Christiansen GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans Dig Dis Sci 34 1989 703 708 (Pubitemid 19139353)
    • (1989) Digestive Diseases and Sciences , vol.34 , Issue.5 , pp. 703-708
    • Schjoldager, B.T.G.1    Mortensen, P.E.2    Christiansen, J.3    Orskov, C.4    Holst, J.J.5
  • 17
    • 60549097258 scopus 로고    scopus 로고
    • Targeting incretins in type 2 diabetes: Role of GLP-1 receptor agonists and DPP-4 inhibitors
    • R.E. Pratley, M. Gilbert Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors Rev Diabet Stud 5 2008 73 94
    • (2008) Rev Diabet Stud , vol.5 , pp. 73-94
    • Pratley, R.E.1    Gilbert, M.2
  • 19
    • 2342599057 scopus 로고    scopus 로고
    • One Week's Treatment with the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and - and Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes
    • DOI 10.2337/diabetes.53.5.1187
    • K.B. Degn, C.B. Juhl, J. Sturis One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 2004 1187 1194 (Pubitemid 38569002)
    • (2004) Diabetes , vol.53 , Issue.5 , pp. 1187-1194
    • Degn, K.B.1    Juhl, C.B.2    Sturis, J.3    Jakobsen, G.4    Brock, B.5    Chandramouli, V.6    Rungby, J.7    Landau, B.R.8    Schmitz, O.9
  • 20
    • 0036189831 scopus 로고    scopus 로고
    • The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
    • DOI 10.1007/s00125-001-0719-z
    • H. Agersø, L.B. Jensen, B. Elbrønd The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 45 2002 195 202 (Pubitemid 34208381)
    • (2002) Diabetologia , vol.45 , Issue.2 , pp. 195-202
    • Agerso, H.1    Jensen, L.B.2    Elbrond, B.3    Rolan, P.4    Zdravkovic, M.5
  • 21
    • 0036676385 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects
    • DOI 10.2337/diacare.25.8.1398
    • B. Elbrønd, G. Jakobsen, S. Larsen Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects Diabetes Care 25 2002 1398 1404 (Pubitemid 41071152)
    • (2002) Diabetes Care , vol.25 , Issue.8 , pp. 1398-1404
    • Elbrond, B.1    Jakobsen, G.2    Larsen, S.3    Agerso, H.4    Jensen, L.B.5    Rolan, P.6    Sturis, J.7    Hatorp, V.8    Zdravkovic, M.9
  • 22
    • 83555169534 scopus 로고    scopus 로고
    • No difference in the pharmacokinetic profile of liraglutide when administered as a single dose to young and elderly healthy subjects
    • (Abstract 460-P)
    • B. Damholt, G. Golor, W. Wierich No difference in the pharmacokinetic profile of liraglutide when administered as a single dose to young and elderly healthy subjects Diabetes 54 Suppl 1 2005 A114 (Abstract 460-P)
    • (2005) Diabetes , vol.54 , Issue.SUPPL. 1 , pp. 114
    • Damholt, B.1    Golor, G.2    Wierich, W.3
  • 23
    • 84855255292 scopus 로고    scopus 로고
    • European Medicines Agency Accessed October 3, 2011
    • European Medicines Agency Victoza (liraglutide) http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/001026/human-med-001137. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125& jsenabled=true Accessed October 3, 2011
    • Victoza (Liraglutide)
  • 24
    • 62449129181 scopus 로고    scopus 로고
    • Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
    • M. Marre, J. Shaw, M. Brndle Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabetic Med 26 2009 268 278
    • (2009) Diabetic Med , vol.26 , pp. 268-278
    • Marre, M.1    Shaw, J.2    Brndle, M.3
  • 25
    • 62449169287 scopus 로고    scopus 로고
    • Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes
    • M.A. Nauck, A. Frid, K. Hermansen Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes Diabetes Care 32 2009 84 90
    • (2009) Diabetes Care , vol.32 , pp. 84-90
    • Nauck, M.A.1    Frid, A.2    Hermansen, K.3
  • 26
    • 59449101432 scopus 로고    scopus 로고
    • Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): Randomized, 52-week, phase III, double-blind, parallel-treatment trial
    • A. Garber, R. Henry, R. Ratner Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomized, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
    • (2009) Lancet , vol.373 , pp. 473-481
    • Garber, A.1    Henry, R.2    Ratner, R.3
  • 27
    • 67650066860 scopus 로고    scopus 로고
    • Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD)
    • B. Zinman, J. Gerich, J. Buse Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD) Diabetes Care 32 2009 1224 1230
    • (2009) Diabetes Care , vol.32 , pp. 1224-1230
    • Zinman, B.1    Gerich, J.2    Buse, J.3
  • 28
    • 69949117621 scopus 로고    scopus 로고
    • Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial
    • D. Russell-Jones, A. Vaag, O. Schmitz Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 52 2009 2046 2055
    • (2009) Diabetologia , vol.52 , pp. 2046-2055
    • Russell-Jones, D.1    Vaag, A.2    Schmitz, O.3
  • 29
    • 77953647320 scopus 로고    scopus 로고
    • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6)
    • 3947
    • J. Buse, J. Rosenstock, G. Sesti Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6) Lancet 4 2009 374 3947
    • (2009) Lancet , vol.4 , pp. 374
    • Buse, J.1    Rosenstock, J.2    Sesti, G.3
  • 30
    • 40049106685 scopus 로고    scopus 로고
    • Hypoglycaemia in Type 2 diabetes
    • DOI 10.1111/j.1464-5491.2007.02341.x
    • S.A. Amiel, T. Dixon, R. Mann Hypoglycaemia in type 2 diabetes Diabet Med 25 2008 245 254 (Pubitemid 351322690)
    • (2008) Diabetic Medicine , vol.25 , Issue.3 , pp. 245-254
    • Amiel, S.A.1    Dixon, T.2    Mann, R.3    Jameson, K.4
  • 31
    • 0032875210 scopus 로고    scopus 로고
    • Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus
    • DOI 10.1046/j.1365-2796.1999.00528.x
    • L. Landstedt-Hallin, A. Englund, U. Adamson, P.E. Lins Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus J Intern Med 246 1999 299 307 (Pubitemid 29426449)
    • (1999) Journal of Internal Medicine , vol.246 , Issue.3 , pp. 299-307
    • Landstedt-Hallin, L.1    Englund, A.2    Adamson, U.3    Lins, P.-E.4
  • 32
    • 78049365082 scopus 로고    scopus 로고
    • Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase
    • M. Malm-Erjeflt, I. Bjørnsdottir, J. Vanggaard Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase Drug Metab Dispos 38 2010 1944 1953
    • (2010) Drug Metab Dispos , vol.38 , pp. 1944-1953
    • Malm-Erjeflt, M.1    Bjørnsdottir, I.2    Vanggaard, J.3
  • 33
    • 70849121250 scopus 로고    scopus 로고
    • Metabolism and excretion of [Pal-3H]-liraglutide in human healthy subjects
    • (Abstract 2107-PO)
    • H. Helleberg, M. Malam-Erjefalt, I. Bjornsdottir Metabolism and excretion of [Pal-3H]-liraglutide in human healthy subjects Diabetes 57 Suppl 1 2008 A581 (Abstract 2107-PO)
    • (2008) Diabetes , vol.57 , Issue.SUPPL. 1 , pp. 581
    • Helleberg, H.1    Malam-Erjefalt, M.2    Bjornsdottir, I.3
  • 34
    • 70849096647 scopus 로고    scopus 로고
    • Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
    • L.V. Jacobsen, C. Hindsberger, R. Robson, M. Zdravkovic Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide Br J Clin Pharmacol 68 2009 898 905
    • (2009) Br J Clin Pharmacol , vol.68 , pp. 898-905
    • Jacobsen, L.V.1    Hindsberger, C.2    Robson, R.3    Zdravkovic, M.4
  • 35
    • 80053582283 scopus 로고    scopus 로고
    • Mild renal impairment has no effect on the efficacy and safety of liraglutide
    • J. Davidson, J. Brett, A. Falahati, D. Scott Mild renal impairment has no effect on the efficacy and safety of liraglutide Endocr Pract 6 2010 1 31
    • (2010) Endocr Pract , vol.6 , pp. 1-31
    • Davidson, J.1    Brett, J.2    Falahati, A.3    Scott, D.4
  • 37
    • 77949393973 scopus 로고    scopus 로고
    • Management of hypertension in the elderly patient
    • G.S. Stokes Management of hypertension in the elderly patient Clin Interv Aging 4 2009 379 389
    • (2009) Clin Interv Aging , vol.4 , pp. 379-389
    • Stokes, G.S.1
  • 39
    • 70350452161 scopus 로고    scopus 로고
    • Alogliptin use in elderly people: A pooled analysis from phase 2 and 3 studies
    • R.E. Pratley, T. McCall, P.R. Fleck Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies J Am Geriatr Soc 57 2009 2011 2019
    • (2009) J Am Geriatr Soc , vol.57 , pp. 2011-2019
    • Pratley, R.E.1    McCall, T.2    Fleck, P.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.